Among these stem cell markers, anti-CD133 therapy has been tested and resulted long-term disease-free tumor survivors, suggesting that anti-CD133 therapy might be associated with drug delivery, forming antibody-drug conjugates that enhance the effect on CD133+ cancer stem cells and increases elimination of CSCs [33]. This evidence concerns the gene PROM1 and cancer.